Dision Medical Completes Tens of Millions RMB Series A Funding to Advance Ophthalmic Device Innovation

Investment Circle (ID: pedaily2012) March 5th, according toArterial Network reported that Shenzhen DisionTech Biomedical Technology Co., Ltd. (referred to as "DisionTech") announced the completionCaused byShenzhen Guochuang Qinzhi Angel FundAndOupcon VisionTens of millions of yuan in Series A round financing from joint investments.This round of financing will mainly be used for the clinical trials of the intelligent corneal cross-linking instrument and the sales promotion of the meibomian gland treatment device.

DisionTech Focuses on Innovation in Ophthalmic Equipment, Aiming for the Domestic Substitution of High-End Ophthalmic Medical Devices

Wei Qingdian, Investment Director of Guochuang ZhiyuanIndicates:DisionTech, as an innovative source of domestically produced ophthalmic devices in China, adheres to a dual-driven approach for product development guided by clinical needs and market demands. Its product portfolio focuses on the premium track of consumer ophthalmology. The intelligent visual meibomian gland massager and the smart patterned corneal cross-linking device can cover the markets for refractive errors and dry eye syndrome, which have the largest patient populations in China. With substantial technological reserves and vast overall market potential, domestically produced ophthalmic medical devices have long been monopolized by imported products. Promoting source-innovative devices is an essential step to breaking the import monopoly, making it worthy of capital attention and investment. Guochuang Qinzhi Fund is honored to participate in this round of investment and looks forward to collaborating with DisionTech's team to advance the successive launches of innovative products, provide better clinical solutions, and bring improved therapeutic benefits to patients.

Tang Ting, Investment Director of OcuScienceRepresentation:OcuScience's overall strategy focuses on full optometry products and full-age optometry services, with key attention to dry eye, refractive optometry examination, treatment equipment, and consumables. The core product pipeline of DisionTech is built around these areas. Backed by Tsinghua University and top ophthalmology specialty hospitals in China, the team demonstrates strong clinical insight and fast engineering transformation. Its handheld thermal pulsation meibomian gland treatment device has obtained the first Chinese production registration certificate and reached a strategic cooperation agreement with leading medical service groups in China, showing promising commercialization prospects. The corneal cross-linking instrument has also passed type inspection and is expected to obtain the first Chinese production registration certificate. This product is mainly used in keratoconus treatment and post-refractive surgery reinforcement, and has the potential for non-invasive refractive surgery. OcuScience looks forward to deepening cooperation with DisionTech in new technologies and products, providing more high-quality products and services for everyone to "see clearly and see better."